---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-003510"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2022-03-14T23:59:59+00:00"
generated_at: "2026-06-26T23:14:57.424245+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Crinetics appoints former Biogen commercial lead Caren Deardorf to board

## Summary
- Caren Deardorf appointed as Class II director, initial term through 2023 annual meeting.
- She brings over 20 years at Biogen, led global commercial efforts for Spinraza in SMA.
- Board size increased from seven to eight members to accommodate the new appointment.
- Deardorf receives annual cash retainer of $40,000 plus $7,500 for committee service; granted 25,000 stock options vesting over 3 years.

## SEC filing metadata
- accession: 0000950170-22-003510
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2022-03-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000095017022003510/0000950170-22-003510-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000095017022003510/crnx-20220311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-003510
- JSON: https://secwatch.observer/filing/0000950170-22-003510.json
- Plain text: https://secwatch.observer/filing/0000950170-22-003510.txt

## Key facts
- Executive change
  Caren Deardorf was appointed as Director at Crinetics Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Director
  source text: the Board approved an increase in its authorized size from seven members to eight members and appointed Caren Deardorf to fill the vacancy created by such increase and serve as a Class II director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000095017022003510/0000950170-22-003510-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.